Dr Patten is a UK-trained clinical haematologist and has been in his current position since 2014, where he provides clinical services for the King’s Health Partners lymphoma service. He is particularly interested in chronic lymphocytic leukaemia (CLL), a common lymphoma subtype, which was the subject matter of his PhD undertaken at King’s College London. From 2009 to 2013, he undertook a LLR/Bloodwise-funded Visiting Fellowship at the Feinstein Institute of Medical Research, New York, USA, returning to take up his Consultant and Senior Lecturer post at the end of that period. Dr Patten is very actively involved in clinical trials for CLL and other lymphomas through full participation in the National Cancer Research Institute portfolio and commercial studies. Further, he continues to undertake laboratory research at KCL investigating these lymphoid disorders, collaborating with national and international researchers. Through membership of the NCRI CLL CSG sub-group and UK CLL Forum Executive he further ensures that clinical and laboratory research, education and advocacy in this disease is maintained at a national level.
Dr Patten is fully trained in the assessment of patients for, and delivery of, CAR-T therapy, a highly specialised new therapy that has recently been licenced for certain patients with relapsed high grade B cell lymphomas and acute lymphoblastic leukaemia. He delivers this within a dedicated specific team for this therapy at King’s College Hospital.
